References
- Emily May LG , KarenT, WendellM. Measuring the return from pharmaceutical innovation 2022. Deloitte (2023). www2.deloitte.com/us/en/pages/life-sciences-and-health-care/articles/measuring-return-from-pharmaceutical-innovation.html
- Berdigaliyev N , AljofanM. An overview of drug discovery and development. Future Med. Chem.12(10), 939–947 (2020).
- Scannell JW , BlanckleyA, BoldonH, WarringtonB. Diagnosing the decline in pharmaceutical R&D efficiency. Nat. Rev. Drug Discov.11(3), 191–200 (2012).
- Jensen EJ . Research expenditures and the discovery of new drugs. J. Ind. Econ.36(1), 83–95 (1987).
- Jentzsch V , OsipenkoL, ScannellJW, HickmanJA. Costs and causes of oncology drug attrition with the example of insulin-like growth factor-1 receptor inhibitors. JAMA Netw. Open6(7), e2324977 (2023).
- AI’s potential to accelerate drug discovery needs a reality check. Nature622(7982), 217 (2023).
- Ringel MS , ScannellJW, BaedekerM, SchulzeU. Breaking Eroom’s law. Nat. Rev. Drug Discov.19(12), 833–834 (2020).
- WadmanM .Merck settles Vioxx lawsuits for $4.85 billion. Nature doi: 10.1038/450324b (2007).
- Guengerich FP . Mechanisms of drug toxicity and relevance to pharmaceutical development. Drug Metab. Pharmacokinet.26(1), 3–14 (2011).
- van der Pol KH , AljofanM, BlinOet al. Drug repurposing of generic drugs: challenges and the potential role for government. Appl. Health Econ. Health Policy21(6), 831–840 (2023).